Allogeneic NK CD19 chimeric antigen receptor (CAR) cells derived from cord blood have a 73% response rate without significant toxic effects in lymphoma and chronic lymphatic leukemia (CLL) patients (50). This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.